Biogen’s pricey muscle drug Spinraza too costly for Britain
LONDON (Reuters) – Biogen’s muscle disease treatment Spinraza has been deemed too expensive for use on Britain’s state-run health service,…
by October Gallery
by October Gallery
LONDON (Reuters) – Biogen’s muscle disease treatment Spinraza has been deemed too expensive for use on Britain’s state-run health service,…